BB102 for liver cancer that has progressed after prior treatment
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, BB102, for people with a type of liver cancer called hepatocellular carcinoma (HCC) that has stopped responding to or was not tolerated with certain prior treatments (like targeted therapy or immunotherapy). It is for those whose cancer cells make too much of a protein called FGF19.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your liver cancer has gotten worse after at least one prior treatment, such as anti-angiogenic therapy or an immunotherapy (like PD-1 or CTLA-4 blockers), or you couldn't tolerate that treatment.
- Your liver cancer has been confirmed by a biopsy and tests show it makes too much FGF19 protein.
- Your cancer is at a stage where it can be treated with systemic therapy (stage B or C by BCLC criteria).
- You have at least one tumor that can be measured on a scan.
- You are in fairly good physical condition (ECOG score 0 or 1).
- Your major organs (like kidneys, liver, bone marrow) are working well enough.
- You are not pregnant and agree to use effective birth control if able to become pregnant, for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ABSK-011, combined with standard care, against a placebo with standard care for people with advanced liver cancer that has a specific marker called FGF19 overexpression. The goal is to see if ABSK-011 can help slow the disease.
This trial tests a personalized treatment plan for people whose advanced liver cancer (hepatocellular carcinoma) has progressed after initial targeted and immune therapy. It aims to find a next-step option tailored to your specific situation.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests a new drug called HH-009 for advanced or inoperable liver cancer (hepatocellular carcinoma, or HCC) that has a specific genetic marker called FGF19. The drug is designed to target this marker and may help slow or shrink the cancer in people whose disease has gotten worse despite previous treatment.
This trial studies a new drug called BB102 that targets a specific protein (FGF19/FGFR4) found on some cancer cells. It is for people with advanced solid tumors, especially liver cancer, who have run out of standard treatment options. The goal is to see if the drug is safe and helps shrink or control the cancer.
This study tests a new cell therapy (called CG-102-12C) for advanced liver cancer that has a specific marker (GPC3) and has stopped responding to standard treatments. The therapy uses your own immune cells, specially trained to attack the cancer. This might be an option if you have tried other treatments and they no longer work or cause bad side effects.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.